Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's a quote from another research paper PDF regarding Somavert (G120R) and Prolanta (G129R):
"The most common antagonist in use contains a substitution of an arginine for glycine 129 (G129R hPRL). G129R hPRL was designed based on a corresponding mutation in human growth hormone, G120R hGH, originally proposed and patented by Genentech, Inc. (South San Francisco, CA) (31). The rationale for this mutation is that glycine 129 is important in site 2 binding based on its small size and neutral charge, so replacing it with a large positively charged residue should interfere with its ability to bind."
Here's the link:
https://etd.ohiolink.edu/!etd.send_file?accession=osu1392968846&disposition=inline
We essentially have the prolactin version of Somavert. If that doesn't get you excited Idk what will.
IMO
If anyone is interested in learning more about the science of our drug Prolanta, I found a 243 page research paper out of Clemson University specifically talking about G120R (Somavert) and G129R (Prolanta).
Check it out:
http://tigerprints.clemson.edu/cgi/viewcontent.cgi?article=1157&context=all_dissertations
Looks like panic sellers weeded out. New base forming. I'd like to see a consistent upward trajectory until trial results. Once people start seeing the potential more and more investors will come aboard. This stock is due.
IMO
That's assuming the noteholders have any interest in converting. So far the OS has remained unchanged since the merger and the level 2 has shown no signs of dilutive MM's.
I think with such compelling scientific data surrounding a potential breakthrough cancer treatment, the noteholders will be holding onto their shares for a big ROI.
IMO
It's also funny to note that when doing research on LFA102 they never mention anything about autophagy, which is the observed method of action for Prolanta. I don't really see how anyone could think these 2 drugs are in any way similar.
Also, LFA102 is targeting breast cancer whereas Prolanta is currently targeting ovarian cancer. So once again, it doesnt make a whole lot of sense to compare them.
IMO
Novartis' LFA102 is not even close to the same as Oncolix G129R.
LFA102 is a monoclonal antibody, which are antibodies produced by a single clone of cells or cell line and consisting of identical antibody molecules.
G129R (Prolanta) is a prolactin receptor antagonist with a single amino acid mutation, which substitutes the 129th position on the peptide chain.
G120R (Somavert) is a human growth hormone receptor antagonist with a single amino acid mutation, which substitutes the 120th position on the peptide chain.
Human growth hormone and prolactin are both pituitary hormones of the same cytokine receptor family. They share 49 of their amino acid residues in identical positions on the peptide chain.
Can you now see how Prolanta and Somavert are more closely related than Prolanta and LFA102? The Novartis method is inferior to Prolanta which has precedent from its sibling drug known as Somavert.
Wen Chen developed both Prolanta and Somavert in the same manner. LFA102 is a completely different method of action which Wen Chen has nothing to do with. This is like comparing marijuana to opiates in terms of pain relief. Different methods of action and different drugs.
IMO
Find another biopharmaceutical company with a promising cancer treatment with as much solid scientific data backing it up that is under a $10m market cap. I don't think you can find one. I think any company with a cancer treatment likely to pass phase I should at the very least be carrying a $100m market cap on speculation alone. That means we should at least be worth $1. If we pass phase II with solid efficacy data, $500m-$800m market cap as we get even closer to a multibillion dollar FDA approved drug. Likely buyout candidate at that point.
CELG purchasing ONCX for $20.
IMO
Basically getting though phase I is just a formality. Prolanta is 99% the same drug as Somavert. If you want to get an idea of how we will perform in phase I, go look at the Somavert trials. The only question that matters and it is what we will find out from completing 2-3 trial phases is: Does antagonizing human prolactin receptors result in an effective cancer treatment as either a monotherapy or combination therapy with chemo?
Based on the data and research, it's pretty much a given that Prolanta will be an effective antagonist, and Dr Wen Chen has already demonstrated that G129R is a pure hPRL receptor antagonist. Does a pure prolactin receptor antagonist actually treat cancer? I don't think it's a coincidence that doctors and scientists have been trying to find an effective way to antagonize human prolactin for the past 20-30 years. They know it plays a major role in many cancers. G129R is the only pure antagonist being developed at the moment. Knowing how effective Somavert is at antagonizing hGH and how similar and related hGH is to hPRL, and that Prolanta is essentially the same drug as Somavert, the odds are pretty good here.
IMO
Here is the letter: https://www.sec.gov/Archives/edgar/data/1584137/000000000017032021/filename1.pdf
Oncolix had to make these changes and it's the reason why we had so many filings that were amended so that they were compliant with the SEC.
Basically all they are saying is that they have to remove efficacy claims because those claims should be made by the FDA based on the trial data. We will have all of that shortly.
Stop the lies!!!
There have actually been at least 3 patients dosed, do some DD.
If Prolanta is on going, Oncolix still doesn't have to update the trial page until April. Sponsors are only required to update it once every 12 months.
Also, it clearly states on the oncolixbio.com site that BioVectra is the contract manufacturer. Not sure why there is any confusion with that?
Phase I was was only partially completed. If you knew anything about how trials worked, you would know that the company isn't forced to update the trial page until the final results are in, which would then have to be audited/peer reviewed. Also, it clearly states 'estimated' completion date. So nice try.
GO ONCX!!!
I can't wait til phase I trials are concluded. It's guaranteed to yield positive results. Prolanta is essentially the same exact drug as Somavert, Which happens to be FDA approved. Prolanta will atleast get to phase III with a high probability of an FDA approval.
Scientists have been trying for years to counteract human prolactin with various drugs and most notably bromocriptine, because they know it plays a huge role in the development and spread tumors as well as chemo resistance. Prolanta is the first pure prolactin antagonist designed and modeled off of Somavert the first pure growth hormone antagonist.
Growth hormone and prolactin share 49 identical amino acid residues along their peptide chains. Somavert aka G120R is an amino acid substitution of 120th amino acid residue position and Prolanta aka G129R is an amino acid substitution of the 129th amino acid residue position. These are 2 of the 49 identical positions that are shared by hGH and hPRL.
Knowing that a near identical drug, Somavert, has successfully made it through FDA trials as a pure hGH antagonist, it's almost a guarantee that Prolanta will make it through FDA trials as a pure hPRL antagonist. Both hGH and hPRL are pituitary hormones that are part of the same cytokine receptor family.
A near identical drug working on a near identical hormone. Smells like Prolanta success!!!
BIG THINGS COMING!!!
GO ONCX!!!
BioVectra only has 5.8% of the voting power...
Michael has sold 2 separate companies in good standing with one going to the Nasdaq. He's a pretty good CEO to be honest.
http://www.getfilings.com/sec-filings/170606/OncBioMune-Pharmaceuticals-Inc_8-K/ex10-7.htm
Omg it must be some weird conspiracy. I found another biopharmaceutical company doing business with Puritan Partnes LLC. WHAT IS GOING ON???!!! Why is an investment financing group getting involved with biopharma's!? What could this mean!? Could it be something sinister!?
.......or is it just business as usual?
Nothing to see here folks.........
Well we know those news items are coming sooner rather than later.
What would you consider to be news of substance? What exactly are you looking for?
We all know the only things that they can announce in the short term are:
-Investing partners and foreign licensing partners
-Acquisition of new drugs for the pipeline
-Second cohort of phase I trial commencing
-Phase I preliminary data
-Phase I final data
Is there anything else above and beyond those items we are expecting?
Yeah they can't disclose any information now that Oncolix is a publicly traded company. That would be insider trading. I spoke with Lisa regarding the previous trial that took place back in 2016. Lisa hadn't heard from Oncolix since that trial ended and the company was still privately held. So unless Lisa was closely following the activities of Oncolix it's highly unlikely she would have known about the reverse merger or the company going public.
Basically your email just confirmed for all of us that Oncolix is back in communication with the trial site and had them sign a confidentiality agreement so they do not disclose any more information to shareholders regarding the ongoing trial. So if one were to connect the dots, that right there tells you that these trials are definitely about to happen and not some BS cohort.
The confidentially agreement is put into effect by the sponsor (Oncolix).
Here is some info regarding confidentiality agreements:
"Please note that some sponsors do not require a CDA prior to releasing a protocol."
That's because a CDA is not required for sponsors of a private company. Sponsors need to request a CDA from the principal investigator, especially if it's a public company.
Here's a link about the CDA's:
https://research.uci.edu/sponsored-projects/clinical-trials/cda.html
Thank you so much for your great DD and confirmation! Trials are just about underway!
Go ONCX!!!
False. Lisa Johnson is allowed to tell me about Oncolix' previous trial especially when the company was privately held.
Oh this explains how Prolanta received backing by the FDA. It all makes sense now.
Nothing that is currently happening with the stock price means anything. Once we get Phase I results, then the price action matters as we will have more of an idea about the value of Oncolix and Prolanta. We also have no idea about the drugs they plan to add to their pipeline.
Legally, the Clinical Trials website has to be updated by April. So if the trial starts next month, they should do everyone a favor and get that CT page updated so that it no longer says recruiting. I feel a lot of investors are skeptical of OTC companies and won't by into the hype until they see action. The PR about recruiting patients doesn't get outsiders excited. Knowing the trials have commenced and CT page updated will be meaningful. If we get some preliminary data and noted signs of efficacy, that should definitely help.
We should be getting new drug acquisition news soon. Also, the next cohort of phase I commencing will be a nice little piece of news as well. I don't think things will be as quiet as you think.
BioVectra is the listed contract manufacturer. If you want a link to their website I can provide it for you.
There should be more attention here. Phase I trial results will get it going. I've been in this for almost a year and I have no problem holding for however long it takes.
Why do you not highlight the part where it says 'estimated'?
Estimated doesn't mean it's a firm cut off. They originally anticipated for that to be the trial end date, but as well know, that is no longer the case. The end date of phase is now 'estimated' to be done sometime before year end.
It will pick up. We've already had new investors join the board. As progress on the trials is made, ONCX will get more attention.
Wow that is an incredible point. Good job!
Great post and extremely informative. Thank you for that. I think diving more into the science and potential of Prolanta would be very beneficial to this board.
Are you buying into the theory that if you can effectively antagonize human prolactin that it will result in reduced tumor weight? Do you believe that Prolactin is a key contributor to human's becoming resistant to chemotherapy?
If those above statements are true, I personally believe Prolanta will be a success, because I believe it will be an effective antagonist.
I believe it will be an effective antagonist because of the research I've started doing on Wen Chens other invention, Somavert. Prolanta was designed using the same amino acid substitution method and they are similar drugs. Somavert effectively antagonizes hGH. hGH and hPRL receptors both belong to a class of closely related cytokine receptors as well as both being very structurally similar pituitary hormones. hGH has 191 amino acid residues and hPRL has 198 amino acid residues. 49 of the amino acid residues between hGH and hPRL share an identical position on the peptide chain.
Prolanta (G129R) was designed as an amino acid substitution with a mutation of the 129th amino acid residue position. Somavert (G120R) was designed as an amino acid substitution with a mutation of 120th amino acid residue position.
Knowing all of this, I believe that Prolanta will be an effective antagonist of hPRL receptors. For me the only question is, will a Prolactin receptor antagonist be enough to effectively fight cancer either as a monotherapy or by improving the efficacy of chemotherapy? That remains to be seen, but the science looks promising.
IMO
Well it's a good thing he's not running Oncolix. You should dig into how many companies the Greenville Health System has run into the ground since they are the majority owner. We already know Redman has a good track record. He's had two companies bought out with one getting to the Nasdaq. Podolski is a small player here, so who really cares what he did with Repros?
And who's website is that? Lol
Hmmm... That's weird, it keeps getting posted on here that Prolanta failed... Maybe we just have to look a lot harder... IDK I am at a complete loss on where these results are...
Where is your link to the trial results where it shows that it failed? I can't seem to find it.
To be fair to Lisa, she had not heard from Oncolix since initial trial had ended, which was back in 2016. I highly doubt she knew when I spoke to her that Oncolix had become a public entity. There is no law saying she cannot discuss information regarding a clinical trial of a private company. Oncolix was a private company at the time when the trial was taking place. She clearly fields calls all day long from people asking about the status of trials. When she initially picked up she was like "aren't you the one that just called me yesterday?". I'm certain that Lisa knows what she can and cannot do in regards to her job and what she is allowed to disclose.
She wasn't giving me any specific details. I asked her why the company had only 3 patients and she said there were a lot more, but they only had enough of the drug to complete 3. I asked if she knew why there was a shortage and she said it was most likely do to finances, but didn't know for sure, and that it happens to smaller biotech's quite often. I also asked her why they didn't post the results on the clinicaltrials.gov website and she replied that its up to the sponsor to update the trial pages and its likely due to the trial being incomplete. I told her about Oncolix claiming that there was evidence of efficacy and if she could elaborate on that. She didn't give any specific details, but said it was a shame that the trial had ended because the patients were improving. I asked her about the safety of Prolanta and she said that the drug was well tolerated by everyone they had tested on. Remember there was less than 18 people that it was tested on, the exact number I have no idea. But if it was big trial with 100's of patients, I am sure that not all of them would have tolerated the drug. It's just a really, really small sample size.
Obviously none of this means a whole lot until the trial is officially complete and we get the final results. But at the very least it is encouraging.
Very interesting stuff you post here. I'm all for learning the science behind Prolanta. I was under the impression that the results from the 2D and 3D cultures for this particular drug wouldn't produce the results typically seen from other cancer drugs since it's not directly attacking the cancer cells. It would make sense that in this environment when used in conjunction with the Paclitaxel (chemo) the results would be better. The reason I say all of this is because I don't see how you can you simulate the mechanism of action in a 2D or 3D culture environment. Prolanta works via autaphagy as a result of human prolactin receptors (hPRL) being antagonized. How could a 2D or 3D culture possibly create a scenario that involves hPRL receptors? Prolanta is fighting cancer in an indirect manner.
I'd love to hear your thoughts on that.
TIA
You're a little behind on the times. Read the last two news releases.
Right now the market only cares about tickers that mention MJ or crypto. Positive phase I results will have the same effect. If I was Oncolix, I'd be looking to acquire an MJ drug treatment to add to the pipeline. The market would go crazy over it if they broke into medicinal MJ.
It's because people were undercutting the ask and when you buy at the lower ask price it shows on the tape as red since it actually lowered the PPS.
Yes look at my other post to you. I realize that I was using the wrong terminology. In most any other situation progress is a good thing. My mistake.